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Background: QT dispersion (Qtd) is defined as the difference between the
maximal and the minimal values of the QT through the peripheral and precor-
dial leads. It is considered as an arrhythmogenic indice. Since STEMI is asso-
ciated with arrhythmias and cardiac arrest the aim of this study was to
investigate the effect of revascularization on corrected QT (QTc) and Qtd
Methods: We conducted a retrospective study in which patients presenting
with acute STEMI who underwent primary percutaneous coronary interven-
tion (PCI) were enrolled. Qtc and Qtd were calculated before, 90 minutes
after, and 24 hours after the procedure.
Results: 54 patients (49 males, 5 females) with a mean age of 55,2 years
were evaluated. The results showed significant reduction in both Qtc
(451,4 ms vs 441,2 ms; p<0.001) and Qtd (59,8 ms vs 34,1 ms, p<0.001)
before and 24 hours after primary PCI when no significant difference was
noticed between the Qtc (451,4 ms vs 446,2 ms; p = 0,17) and Qtd (59,8 ms
vs 57,6 ms; p = 0,15) before and 90 minutes after the procedure.
Conclusion: Our Study showed that primary PCI was effective in reducing
Qtc and Qtd after 24 hours although it showed no effect on these arrhythmo-
genic indices 90 minutes after successful revascularization with PPCI. These
findings suggest that ischemia-induced Qtd and prolonged Qtc are important
arrhythmogenic parameters responding to successful PPCI and may be used as
markers for successful PPCI after 24 hours.
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Background: No-reflow in ST-segment elevation acute myocardial infarc-
tion (STEMI) is associated with a poor clinical prognosis. Its pathophysiologal
mechanisms are not totally elucidated yet but enhanced vascular permeability
plays a key role in this process. ANGPTL4 has been implicated in vascular
permeability in experimental models of AMI. We therefore sought to investi-
gate whether baseline ANGPTL4 serum levels are associated with no-reflow
after primary percutaneous coronary intervention (PPCI).
Methods: A group of 41 consecutive patients with a first STEMI, under-
going successful PPCI within 12h of onset of symptoms were enrolled. Blood
samples were obtained from all patients on admission for ANGPTL4 levels
measurement. No-reflow was assessed by cardiac magnetic resonance imaging
(MRI), the reference method.
Results: MRI-detected no-reflow was observed in 20 patients (48.8%).
Variables independently associated with no-reflow at multivariate logistic
regression analysis were: lower ANGPTL4 plasma levels (odds ratio 0.82,
95% CI 0.70-0.98, P=0.02), higher troponin T peak (odds ratio 1.03, 95% CI
1.00-1.05, P=0.03), higher incidence of left anterior descending coronary
artery (LAD) as culprit artery (odds ratio 14.61, 95% CI 1.24-172.49, P=0.03),
and higher C-reactive protein levels (odds ratio 1.18, 95% CI 1.00-1.39,
P=0.05).
Conclusion: ANGPTL4 serum levels predict MRI-detected no-reflow after
successful PPCI in STEMI patients. Given the recently demonstrated thera-
peutic role of ANGPTL4 in diminishing no-reflow and therefore infarct size
in pre-clinical animal models, these findings in humans may open new fields
of research.
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Introduction: The innate immune system has recently been shown to be
important in cardiac response to MI. TREM-1 is an immune-receptor
expressed by neutrophils, macrophages, and mature monocytes that acts as an
amplifier of the innate immune response triggered by Toll-Like Receptors
(TLRs) engagement. We here aim at investigating the mechanisms by which
LR12 confers protection.
Material and method: We used adult male mice TREM-1-/-, Rag1-/-
(lacking B and T cells) and mice depleted in neutrophils with anti-Ly6G 1A8.
Animals were submitted to a permanent MI and then randomized to receive
LR12 (a synthetic TREM-1 inhibitory peptide), LR12 scramble or anti-
TREM-1 mAb (as a TREM-1 agonist) ip beginning 1 hour after MI, then daily
for 5 days.
Results: In different types of mice, we first observed that TREM-1 was
expressed (except in TREM-1-/- ) in myocardial tissue, especially in infarcted
areas with an expression peaking at 24h after MI. We next observed that in
TREM-1-/- and LR12 treated animals infarct size was reduced. Recruitment of
inflammatory cells (neutrophils, Ly6Chimonocytes, B cells) was also reduced,
while ‘anti-inflammatory’ Ly6Clow monocytes number was increased. In LR12
treated and TREM-1-/- mice we observed a reduction of leucocytes activation.
Using both qRT-PCR and zymography we found that deletion or modulation
of TREM-1 was associated with a decreased protease activity in infarcted
areas (MMP9/TIMP1). Finally, while activation of TREM-1 through anti-
TREM-1 mAb administration decreased survival, LR12 and deletion of
TREM-1 conferred protection. The phenomena obtained in TREM-1-/- and
LR12 treated was also observed in Rag1-/-and mice depleted in neutrophils.
Conclusion: TREM-1 plays an important role in mediating inflammatory
cells recruitment and activation following myocardial infarction. Its thera-
peutic modulation achieved through LR12 administration confers protection in
mice.
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